No effect of CYP450 and P‐glycoprotein on hydroxyurea in vitro metabolism

Our objectives were (1) to study the HU metabolism via human cytochromes and (2) to test if HU is a substrate of P‐gp. HU metabolism was investigated by determining the appearance of urea and HU decreasing upon incubation with human liver microsomes. Quantification was determined using HPLC coupled with UV‐detection at 449 nm. Our method was linear between 5 and 1000 μm, precise (coefficients of variation ranging from 1.7 to 9.9%), accurate (97.7–103.9%). The limit of quantification was 7 μm. The ATPase activity of human P‐gp membranes was determined by measuring inorganic phosphate liberation. HU and urea measurements in microsomes were not different between 0 and 60 min whatever HU concentration used from 30 to 300 μm. The presence of NADPH in the medium has no effect on HU and urea measurements. In the absence of verapamil, the ATPase activity was unaffected by HU at concentrations of 10, 30, 100 and 300 μm. HU is unlikely to cause clinically relevant drug interactions with the substrates of these enzymes/transporters. However, it will be necessary to validate these in vitro data in patients with sickle cell anemia to evaluate the impact of genetic polymorphisms of these enzymes in a black population.

[1]  David C. Smith,et al.  Population pharmacokinetics of hydroxyurea in cancer patients , 2009, Cancer Chemotherapy and Pharmacology.

[2]  D. Bachir,et al.  Plasma and Urine Hydroxyurea Levels Might be Useful in the Management of Adult Sickle Cell Disease , 2007, Hemoglobin.

[3]  J. Schellens,et al.  The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate , 2007, Cancer Chemotherapy and Pharmacology.

[4]  G. Camenisch,et al.  Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier , 2006, Drug Metabolism and Disposition.

[5]  Jinming Huang,et al.  Rat liver-mediated metabolism of hydroxyurea to nitric oxide. , 2006, Free Radical Biology & Medicine.

[6]  A. di Pietro,et al.  Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2) , 2006, Anti-cancer drugs.

[7]  J. Schellens,et al.  Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer , 2006, Clinical pharmacokinetics.

[8]  F. Roudot-thoraval,et al.  Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. , 2006, Haematologica.

[9]  Allan H Friedman,et al.  Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Asakura,et al.  Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy , 2005, British journal of haematology.

[11]  G. Dresemann Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  S. Thein,et al.  The measurement of urinary hydroxyurea in sickle cell anaemia , 2005, British journal of haematology.

[13]  K. Ataga,et al.  The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease , 2005, Journal of clinical pharmacology.

[14]  S. King Nitric oxide production from hydroxyurea. , 2004, Free radical biology & medicine.

[15]  Jinming Huang,et al.  Catalase-mediated nitric oxide formation from hydroxyurea. , 2004, Journal of medicinal chemistry.

[16]  L. Mangravite,et al.  Characterizing the Expression of CYP3A4 and Efflux Transporters (P-gp, MRP1, and MRP2) in CYP3A4-Transfected Caco-2 Cells After Induction with Sodium Butyrate and the Phorbol Ester 12-O-Tetradecanoylphorbol-13-Acetate , 2001, Pharmaceutical Research.

[17]  S. Swindells,et al.  Pharmacokinetics of Hydroxyurea in Plasma and Cerebrospinal Fluid of HIV‐1‐Infected Patients , 2003, Journal of clinical pharmacology.

[18]  E. Vichinsky,et al.  Hydroxyurea and Arginine Therapy: Impact on Nitric Oxide Production in Sickle Cell Disease , 2003, Journal of pediatric hematology/oncology.

[19]  S. Ballas,et al.  Urease enhances the formation of iron nitrosyl hemoglobin in the presence of hydroxyurea. , 2003, Biochimica et biophysica acta.

[20]  O. Castro,et al.  Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea , 2002, British journal of haematology.

[21]  Valentine J. Burroughs,et al.  Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. , 2002, Journal of the National Medical Association.

[22]  Jinming Huang,et al.  Horseradish peroxidase catalyzed nitric oxide formation from hydroxyurea. , 2002, Journal of the American Chemical Society.

[23]  M. Gladwin,et al.  Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease , 2002, British journal of haematology.

[24]  L. Benet,et al.  The drug efflux-metabolism alliance: biochemical aspects. , 2001, Advanced drug delivery reviews.

[25]  H. Fasold,et al.  Hydroxyurea‐induced oxidative damage of normal and sickle cell hemoglobins in vitro: Amelioration by radical scavengers , 2001, Journal of clinical laboratory analysis.

[26]  P. Okunieff,et al.  Cellular and biophysical evidence for interactions between adenosine triphosphate and P-glycoprotein substrates: functional implications for adenosine triphosphate/drug cotransport in P-glycoprotein overexpressing tumor cells and in P-glycoprotein low-level expressing erythrocytes. , 2001, Blood cells, molecules & diseases.

[27]  J. Lisziewicz,et al.  Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[29]  A. D. Rodrigues,et al.  Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[30]  P. Gwilt,et al.  Pharmacokinetics and Pharmacodynamics of Hydroxyurea , 1998, Clinical pharmacokinetics.

[31]  P. Gwilt,et al.  Colorimetric determination of hydroxyurea in human serum using high-performance liquid chromatography. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[32]  G. Weiss,et al.  A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. , 1998, Blood.

[33]  H. Maeda,et al.  In vivo production of nitric oxide in rats after administration of hydroxyurea. , 1997, Molecular pharmacology.

[34]  D. Schrenk,et al.  Expression of the multidrug resistance genes in the liver , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  F. Lori,et al.  Pharmacokinetics of Hydroxyurea in Patients Infected with Human Immunodeficiency Virus Type I , 1996, Journal of clinical pharmacology.

[36]  M L Terrin,et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.

[37]  P. Gwilt,et al.  Nonlinear disposition of hydroxyurea. , 1994, Journal of pharmaceutical sciences.

[38]  R. Boucher,et al.  Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. , 1992, The Journal of biological chemistry.

[39]  M. Vacca,et al.  Hydroxyurea: relationship between toxicity and centrally-induced adrenal activation. , 1990, Pharmacology & toxicology.

[40]  M. Goldberg,et al.  Treatment of sickle cell anemia with hydroxyurea and erythropoietin. , 1990, The New England journal of medicine.

[41]  A. Schechter,et al.  Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. , 1990, The New England journal of medicine.

[42]  J. Wright,et al.  Evidence that the antitumor agent hydroxyurea enters mammalian cells by a diffusion mechanism. , 1986, Biochemical and biophysical research communications.

[43]  U. Andrae Evidence for the involvement of cytochrome P-450-dependent monooxygenase(s) in the formation of genotoxic metabolites from N-hydroxyurea. , 1984, Biochemical and biophysical research communications.

[44]  R. Belt,et al.  Studies of hydroxyurea administered by continuous infusion. Toxicity, pharmacokinetics, and cell synchronization , 1980, Cancer.

[45]  M. Colvin,et al.  The enzymatic reduction of hydroxyurea to urea by mouse liver. , 1970, Cancer research.

[46]  R. Adamson,et al.  The distribution, excretion and metabolism of hydroxyurea-C14. , 1965, The Journal of pharmacology and experimental therapeutics.